Clinical use of gatifloxacin ophthalmic solution for treatment of bacterial conjunctivitis

Código QR

Clinical use of gatifloxacin ophthalmic solution for treatment of bacterial conjunctivitis

Lorenzo J Cervantes, Francis S MahDepartment of Ophthalmology, Cornea and External Disease, University of Pittsburgh Medical Center, Pittsburgh, Pennsylvania, USAAbstract: Bacterial conjunctivitis is a common infectious disease of the eye, characterized by conjunctival hyperemia, eyelid edema, and p...

Descripción completa

Guardado en:

Detalles Bibliográficos
Autores principales:	Cervantes LJ, Mah FS
Formato:	article
Lenguaje:	EN
Publicado:	Dove Medical Press 2011
Materias:	Ophthalmology RE1-994
Acceso en línea:	https://doaj.org/article/4a065ecae35f4ce190c02a2c3d4007c7
Etiquetas:	Agregar Etiqueta Sin Etiquetas, Sea el primero en etiquetar este registro!

Ejemplares similares

Treatment of allergic conjunctivitis with bepotastine besilate ophthalmic solution 1.5%
por: Bergmann MT, et al.
Publicado: (2014)

Update and clinical utility of alcaftadine ophthalmic solution 0.25% in the treatment of allergic conjunctivitis
por: Chigbu DI, et al.
Publicado: (2015)

Azelastine hydrochloride, a dual-acting anti-inflammatory ophthalmic solution, for treatment of allergic conjunctivitis
por: Patricia B Williams, et al.
Publicado: (2010)

Besifloxacin ophthalmic suspension 0.6% in the treatment of bacterial conjunctivitis patients with Pseudomonas aeruginosa infections
por: Silverstein BE, et al.
Publicado: (2012)

Integrated analysis of three bacterial conjunctivitis trials of besifloxacin ophthalmic suspension, 0.6%: etiology of bacterial conjunctivitis and antibacterial susceptibility profile
por: Haas W, et al.
Publicado: (2011)

Review of moxifloxacin hydrochloride ophthalmic solution in the treatment of bacterial eye infections
por: Darlene Miller
Publicado: (2008)

Integrated analysis of three bacterial conjunctivitis trials of besifloxacin ophthalmic suspension, 0.6%: microbiological eradication outcomes
por: Morris TW, et al.
Publicado: (2011)

Clinical utility of 3% diquafosol ophthalmic solution in the treatment of dry eyes
por: Koh S
Publicado: (2015)

Critical appraisal of bepotastine in the treatment of ocular itching associated with allergic conjunctivitis
por: Jeremy B Wingard, et al.
Publicado: (2011)

Besifloxacin: a novel anti-infective for the treatment of bacterial conjunctivitis
por: Timothy L Comstock, et al.
Publicado: (2010)

Safety of cetirizine ophthalmic solution 0.24% for the treatment of allergic conjunctivitis in adult and pediatric subjects
por: Malhotra RP, et al.
Publicado: (2019)

Clinical utility of cyclosporine (CsA) ophthalmic emulsion 0.05% for symptomatic relief in people with chronic dry eye: a review of the literature
por: Rhee MK, et al.
Publicado: (2017)

Evaluation of alcaftadine 0.25% ophthalmic solution in acute allergic conjunctivitis at 15 minutes and 16 hours after instillation versus placebo and olopatadine 0.1%
por: Jack V Greiner, et al.
Publicado: (2011)

Intraocular penetration of sequentially instilled topical moxifloxacin, gatifloxacin, and levofloxacin
por: Koji Sugioka, et al.
Publicado: (2009)

Influence of container structures and content solutions on dispensing time of ophthalmic solutions
por: Keiji Yoshikawa, et al.
Publicado: (2010)

Concentrations of besifloxacin, gatifloxacin, and moxifloxacin in human conjunctiva after topical ocular administration
por: Gail Torkildsen, et al.
Publicado: (2010)

A 3-day regimen with azithromycin 1.5% eyedrops for the treatment of purulent bacterial conjunctivitis in children: efficacy on clinical signs and impact on the burden of illness
por: Bremond-Gignac D, et al.
Publicado: (2015)

Latanoprost ophthalmic solution in the treatment of open angle glaucoma or raised intraocular pressure: a review
por: Andrea Russo, et al.
Publicado: (2009)

Comparative efficacy of bepotastine besilate 1.5% ophthalmic solution versus olopatadine hydrochloride 0.2% ophthalmic solution evaluated by patient preference
por: McCabe CF, et al.
Publicado: (2012)

Treatment of allergic conjunctivitis with olopatadine hydrochloride eye drops
por: Eiichi Uchio
Publicado: (2008)

Update and critical appraisal of the use of topical azithromycin ophthalmic 1% (AzaSite&reg;) solution in the treatment of ocular infections
por: Utine CA
Publicado: (2011)

Evaluation of analgesic efficacy of bromfenac sodium ophthalmic solution 0.09% versus ketorolac tromethamine ophthalmic solution 0.5% following LASEK or Epi-LASIK
por: Wang XJ, et al.
Publicado: (2011)

Efficacy and tolerability of a combined gatifloxacin plus prednisolone formulation for topical prophylaxis after LASIK
por: Mauro Campos, et al.
Publicado: (2011)

Kinetics of kill of bacterial conjunctivitis isolates with moxifloxacin, a fluoroquinolone, compared with the aminoglycosides tobramycin and gentamicin
por: Rudolph S Wagner, et al.
Publicado: (2010)

Ocular pharmacokinetics and tolerability of bimatoprost ophthalmic solutions administered once or twice daily in rabbits, and clinical dosing implications [Corrigendum]
por: Shen J, et al.
Publicado: (2018)

The role of difluprednate ophthalmic emulsion in clinical practice
por: Karim N Jamal, et al.
Publicado: (2009)

Potential bias in ophthalmic pharmaceutical clinical trials
por: Paul Varner
Publicado: (2008)

Incidence of deepening of upper eyelid sulcus after topical use of tafluprost ophthalmic solution in Japanese patients
por: Maruyama K, et al.
Publicado: (2013)

Phase III trials examining the efficacy of cetirizine ophthalmic solution 0.24% compared to vehicle for the treatment of allergic conjunctivitis in the conjunctival allergen challenge model
por: Meier EJ, et al.
Publicado: (2018)

Sustained intraocular pressure reduction throughout the day with travoprost ophthalmic solution 0.004%
por: Dubiner HB, et al.
Publicado: (2012)

Clinical utility of voriconazole eye drops in ophthalmic fungal keratitis
por: Daoud Al-Badriyeh, et al.
Publicado: (2010)

Safety and efficacy of MIM D3 ophthalmic solutions in a randomized placebo controlled Phase 2 clinical trial in patients with dry eye
por: Meerovitch K, et al.
Publicado: (2013)

An evidence-based review of unoprostone isopropyl ophthalmic solution 0.15% for glaucoma: place in therapy
por: Fung DS, et al.
Publicado: (2014)

Review of hydroxypropyl cellulose ophthalmic inserts for treatment of dry eye
por: Nguyen T, et al.
Publicado: (2011)

Thymosin beta 4 ophthalmic solution for dry eye: a randomized, placebo-controlled, Phase II clinical trial conducted using the controlled adverse environment (CAE™) model
por: Sosne G, et al.
Publicado: (2015)

The significance of the determination of lymphocytes with clinical manifestation of ophthalmic zoster sine herpete
por: Tatsuya Marumoto, et al.
Publicado: (2010)

Assessment of the tolerability profile of an ophthalmic solution of 5% glycyrrhizin and copolymer PEG/PPG on healthy volunteers and evaluation of its efficacy in the treatment of moderate to severe blepharitis
por: Mencucci R, et al.
Publicado: (2013)

Efficacy, safety, and improved tolerability of travoprost BAK-free ophthalmic solution compared with prior prostaglandin therapy
por: J Charles Henry, et al.
Publicado: (2008)

The ocular distribution of 14C-labeled bromfenac ophthalmic solution 0.07% in a rabbit model
por: Baklayan GA, et al.
Publicado: (2014)

Topical ophthalmic NSAIDs: a discussion with focus on nepafenac ophthalmic suspension
por: Bruce I Gaynes, et al.
Publicado: (2008)